Axion BioSystems Revenue and Competitors

Atlanta, GA USA

Location

$20.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Axion BioSystems's estimated annual revenue is currently $39.9M per year.(i)
  • Axion BioSystems received $6.0M in venture funding in May 2016.
  • Axion BioSystems's estimated revenue per employee is $193,750
  • Axion BioSystems's total funding is $20.3M.

Employee Data

  • Axion BioSystems has 206 Employees.(i)
  • Axion BioSystems grew their employee count by -15% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$1.1M7-36%N/AN/A
#2
$1.7M11-8%N/AN/A
#3
$1.6M10-17%N/AN/A
#4
$1.4M90%N/AN/A
#5
$17.1M1105%$0.07BN/A
#6
$4.3M284%N/AN/A
#7
$1.1M70%N/AN/A
#8
$1.1M740%N/AN/A
#9
$7.6M49-4%N/AN/A
#10
$1.9M120%N/AN/A
Add Company

Axion BioSystems is the leader in microelectrode array (MEA) data acquisition and analysis. With the Maestro MEA platform, functional activity assays on neural or cardiomyocyte cell networks are easily performed on the benchtop facilitating investigations in neurotoxicology, cardiac safety, in vitro disease modeling, and drug discovery. Scalability options from 12- to 96-wells and a new automation system, Maestro APEX, meets high throughput screening needs as well as assay development and follow-up studies - all with a single system. Looking to incorporate cutting-edge technology into your research High-throughput optogenetic stimulation (Lumos) is an available option to add to your Maestro, enabling simultaneous fine-tuned cellular control and real-time functional activity assessment. Tying this all together is AxIS, the integrated acquisition and analysis program that makes every MEA assay from experiment start to completed analysis simple and straightforward.

keywords:Biotechnology,Cleantech,Healthcare,Medical Devices,Pharmaceuticals,Wind Power

$20.3M

Total Funding

206

Number of Employees

$39.9M

Revenue (est)

-15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Axion BioSystems News

2022-04-17 - Microelectrode Arrays (MEAs) Market Size, Outlook And Forecast ...

MaxWell Biosystems, Axion Biosystems, Multi Channel Systems MCS GmbH, Med64, 3Brain. Microelectrode Arrays (MEAs) Market Segmentation:.

2022-04-17 - Neuroscience Market Size And Forecast | Alpha Omega GE ...

Alpha Omega GE Healthcare, Axion Biosystems Siemens Healthineers, Scientifica Ltd., Blackrock Microsystems LLC, Femtonics Ltd.,...

2022-02-22 - Axion BioSystems Expands Operations with Acquisition of M-Solv ...

ATLANTA--(BUSINESS WIRE)--Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies,...

2021-07-16 - Summa Equity acquires Axion BioSystems, to accelerate understanding of cell behaviour in drug discovery and development

Summa Equity acquires Axion BioSystems, to accelerate understanding of cell behaviour in drug discovery and development Fri, Jul 16, 2021 14:00 CET Summa Equity Fund II has acquired Axion BioSystems, a US life science tools business specializing in the development, production, and marketing of ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$57.6M206-1%N/A
#2
$60.1M2078%$73.3M
#3
$69.4M20716%N/A
#4
$33M20717%N/A
#5
$57.2M20780%N/A

Axion BioSystems Funding

DateAmountRoundLead InvestorsReference
2016-05-17$6.0MUndisclosedThe Georgia Research AllianceArticle